Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?

Herman Autrupa Institute of Public Health, University of Aarhus, Aarhus, Denmark

Frank A. Barileb College of Pharmacy and Health Sciences, St John’s University, Queens, USA

Sir Colin Berryc Queen Mary University of London, UK

Bas J. Blaauboerd Division of Toxicology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands

Alan Boobise National Heart & Lung Institute, Imperial College, London, UK

Herrmann Boltf Leibniz Research Centre for Working Environment and Human Factors (Ifado), TU Dortmund, Dortmund, Germany

Christopher J. Borgertg Applied Pharmacology and Toxicology, Inc. Gainesville, USA

Wolfgang Dekanth Department of Toxicology, University of Wuerzburg, Wuerzburg, Germany

Daniel Dietrichi Human and Environmental Toxicology, University of Konstanz, Konstanz, Germany

Jose L. Domingoj Laboratory of Toxicology and Environmental Health, School of Medicine, IISPV, Universitat ‘Rovira I Virgili’, Reus, Spain

Gio Batta Gorik The Health Policy Center, Bethesda, USA

Helmut Greiml Technical University of MunichD-85350, Freising-Weihenstephan, Germany

Jan Hengstlerf Leibniz Research Centre for Working Environment and Human Factors (Ifado), TU Dortmund, Dortmund, Germany

Sam Kacewm McLaughlin Centre for Risk Assessment, University of Ottawa, Ottawa, Canada

Hans Marquardtn Toxicology, Hamburg, Germany

Olavi Pelkoneno Department of Pharmacology and Toxicology, University of Oulu, Finland

Kai Savolainenp Nanosafety Research Centre, Finnish Institute of Occupational Health, Helsinki, Finland

Pat Heslop-Harrisonq Department of Genetics and Genome Biology, University of Leicester, Leicester, UK

Nico P. Vermeulenr Department of Chemistry & Pharmaceutical Sciences, Vrije Universiteit, Amsterdam, The Netherlands

Your download is now in progress and you may close this window